Zejula, Lynparza, and Rubraca have been voluntarily withdrawn for late-line ovarian cancer treatment indications over concerns surrounding an increased risk for death.
Medscape Medical News
Drug Companies Withdraw PARPi Indications for Ovarian Cancer
